Literature DB >> 18955133

Molecular mechanisms of alpha-synuclein neurodegeneration.

Elisa A Waxman1, Benoit I Giasson.   

Abstract

alpha-Synuclein is an abundant highly charged protein that is normally predominantly localized around synaptic vesicles in presynaptic terminals. Although the function of this protein is still ill-defined, genetic studies have demonstrated that point mutations or genetic alteration (duplications or triplications) that increase the number of copies of the alpha-synuclein (SCNA) gene can cause Parkinson's disease or the related disorder dementia with Lewy bodies. alpha-Synuclein can aberrantly polymerize into fibrils with typical amyloid properties, and these fibrils are the major component of many types of pathological inclusions, including Lewy bodies, which are associated with neurodegenerative diseases, such as Parkinson's disease. Although there is substantial evidence supporting the toxic nature of alpha-synuclein inclusions, other modes of toxicity such as oligomers have been proposed. In this review, some of the evidence for the different mechanisms of alpha-synuclein toxicity is presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955133      PMCID: PMC2756732          DOI: 10.1016/j.bbadis.2008.09.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  164 in total

1.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies.

Authors:  K Wakabayashi; M Yoshimoto; T Fukushima; R Koide; Y Horikawa; T Morita; H Takahashi
Journal:  Neuropathol Appl Neurobiol       Date:  1999-10       Impact factor: 8.090

4.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

5.  Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

Authors:  C F Lippa; M L Schmidt; V M Lee; J Q Trojanowski
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

6.  Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?

Authors:  A Papadimitriou; V Veletza; G M Hadjigeorgiou; A Patrikiou; M Hirano; I Anastasopoulos
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

7.  Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

Review 8.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01

9.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.

Authors:  P H Jensen; M S Nielsen; R Jakes; C G Dotti; M Goedert
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

View more
  84 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Alpha-synuclein loss in spinal muscular atrophy.

Authors:  Gyula Acsadi; Xingli Li; Kelley J Murphy; Kathryn J Swoboda; Graham C Parker
Journal:  J Mol Neurosci       Date:  2010-07-17       Impact factor: 3.444

3.  Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.

Authors:  Amanda N Sacino; Mieu Brooks; Michael A Thomas; Alex B McKinney; Nicholas H McGarvey; Nicola J Rutherford; Carolina Ceballos-Diaz; Janice Robertson; Todd E Golde; Benoit I Giasson
Journal:  Acta Neuropathol       Date:  2014-05       Impact factor: 17.088

Review 4.  Systems biology of neurodegenerative diseases.

Authors:  Levi B Wood; Ashley R Winslow; Samantha Dale Strasser
Journal:  Integr Biol (Camb)       Date:  2015-07       Impact factor: 2.192

5.  DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity.

Authors:  Chenere P Ramsey; Elpida Tsika; Harry Ischiropoulos; Benoit I Giasson
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

6.  Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons.

Authors:  João Paulo L Daher; Mingyao Ying; Rebecca Banerjee; Rebecca S McDonald; Myriam Dumas Hahn; Lichuan Yang; M Flint Beal; Bobby Thomas; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  Mol Neurodegener       Date:  2009-07-24       Impact factor: 14.195

7.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 8.  Synapse pathology in psychiatric and neurologic disease.

Authors:  Myrrhe van Spronsen; Casper C Hoogenraad
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

9.  Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.

Authors:  Bwarenaba B Kautu; Alejandro Carrasquilla; Matthew L Hicks; Kim A Caldwell; Guy A Caldwell
Journal:  Neurosci Lett       Date:  2013-02-26       Impact factor: 3.046

10.  Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.

Authors:  Andrew O Koob; Kiren Ubhi; Johan F Paulsson; Jeffery Kelly; Edward Rockenstein; Michael Mante; Anthony Adame; Eliezer Masliah
Journal:  Exp Neurol       Date:  2009-11-26       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.